<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30886246</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice.</ArticleTitle><Pagination><StartPage>4805</StartPage><MedlinePgn>4805</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4805</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-41285-z</ELocationID><Abstract><AbstractText>Besides causing mild hand, foot and mouth infections, Enterovirus A71 (EV-A71) is associated with neurological complications and fatality. With concerns about rising EV-A71 virulence, there is an urgency for more effective vaccines. The live attenuated vaccine (LAV) is a more valuable vaccine as it can elicit both humoral and cellular immune responses. A miRNA-based vaccine strain (pIY) carrying let-7a and miR-124a target genes in the EV-A71 genome which has a partial deletion in the 5'NTR (&#x2206;11&#x2009;bp) and G64R mutation (3D<sup>p</sup>&#xb0;<sup>l</sup>) was designed. The viral RNA copy number and viral titers of the pIY strain were significantly lower in SHSY-5Y cells that expressed both let-7a and miR-124a. Inhibition of the cognate miRNAs expressed in RD and SHSY-5Y cells demonstrated de-repression of viral mRNA translation. A previously constructed multiply mutated strain, MMS and the pIY vaccine strain were assessed in their ability to protect 4-week old mice from hind limb paralysis. The MMS showed higher amounts of IFN-&#x3b3; ex vivo than the pIY vaccine strain. There was absence of EV-A71 antigen in the skeletal muscles and spinal cord micrographs of mice vaccinated with the MMS and pIY strains. The MMS and pIY strains are promising LAV candidates developed against severe EV-A71 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Pinn Tsin Isabel</ForeName><Initials>PTI</Initials><AffiliationInfo><Affiliation>Centre for Virus and Vaccine Research, School of Science and Technology, Sunway University, Bandar Sunway, Selangor, 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Soon Hao</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, University of Malaya, Jalan University, 50603, Kuala Lumpur, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Kien Chai</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, University of Malaya, Jalan University, 50603, Kuala Lumpur, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Kuan Onn</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Science and Technology, Sunway University, Kuala Lumpur, Selangor, 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kum Thong</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, University of Malaya, Jalan University, 50603, Kuala Lumpur, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Sharifah Syed</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Jalan Lagoon Selatan, Bandar Sunway, 47500, Subang Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Chit Laa</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Centre for Virus and Vaccine Research, School of Science and Technology, Sunway University, Bandar Sunway, Selangor, 47500, Malaysia. pohcl@sunway.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509207">MIRN124 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487931">mirnlet7 microRNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30886246</ArticleId><ArticleId IdType="pmc">PMC6423319</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-41285-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-41285-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. The Lancet Neurology. 2010;9:1097&#x2013;1105. doi: 10.1016/s1474-4422(10)70209-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(10)70209-x</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing, W. et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis14, 10.1016/s1473-3099(13)70342-6 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: Outbreaks of Coxsackieviruses A10. Journal of Medical Virology. 2015;87:954&#x2013;960. doi: 10.1002/jmv.24151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N, Lennette E, Ho H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick, J. In Viral Infections of Humans (eds AlfredS Evans &amp; RichardA Kaslow) Ch. 21, 583&#x2013;663 (Springer US, 1997).</Citation></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) Expert Review of Vaccines. 2016;15:599&#x2013;606. doi: 10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber, R. S., van Beek, J., de Jonge, J., Luytjes, W. &amp; van Baarle, D. T Cell responses to viral infections &#x2013; opportunities for peptide vaccination. Frontiers in Immunology5, 10.3389/fimmu.2014.00171 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997009</ArticleId><ArticleId IdType="pubmed">24795718</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466&#x2013;471. doi: 10.1203/01.pdr.0000238247.86041.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, et al. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol. 2013;191:1637&#x2013;1647. doi: 10.4049/jimmunol.1301439.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301439</ArticleId><ArticleId IdType="pubmed">23863902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281&#x2013;297. doi: 10.1016/S0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host &amp; Microbe. 2008;4:239&#x2013;248. doi: 10.1016/j.chom.2008.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.003</ArticleId><ArticleId IdType="pmc">PMC2605097</ArticleId><ArticleId IdType="pubmed">18779050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136:215&#x2013;233. doi: 10.1016/j.cell.2009.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.01.002</ArticleId><ArticleId IdType="pmc">PMC3794896</ArticleId><ArticleId IdType="pubmed">19167326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamore PD, Haley B. Ribo-gnome: The big rorld of small RNAs. Science. 2005;309:1519&#x2013;1524. doi: 10.1126/science.1111444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1111444</ArticleId><ArticleId IdType="pubmed">16141061</ArticleId></ArticleIdList></Reference><Reference><Citation>Isabel PT, Chit Laa P. Development of novel miRNA-based vaccines and antivirals against enterovirus 71. Current Pharmaceutical Design. 2016;22:1&#x2013;7. doi: 10.2174/1381612822666160720165613.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666160720165613</ArticleId><ArticleId IdType="pubmed">27510488</ArticleId></ArticleIdList></Reference><Reference><Citation>P T Isabel Y, Tan KO, Othman I, Poh CL. Identification of molecular determinants of cell culture growth characteristics of enterovirus 71. Virology Journal. 2016;13:194. doi: 10.1186/s12985-016-0645-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0645-9</ArticleId><ArticleId IdType="pmc">PMC5126835</ArticleId><ArticleId IdType="pubmed">27894305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, et al. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. Journal of Neuropathology &amp; Experimental Neurology. 2008;67:532&#x2013;542. doi: 10.1097/NEN.0b013e31817713e7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713e7</ArticleId><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LCS, et al. Fatal enterovirus 71 encephalomyelitis. The Journal of Pediatrics. 1998;133:795&#x2013;798. doi: 10.1016/S0022-3476(98)70155-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(98)70155-6</ArticleId><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Reviews in Medical Virology. 2015;25:115&#x2013;128. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6:4&#x2013;14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, et al. Two-year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Review of Vaccines. 2016;15:129&#x2013;137. doi: 10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88:5803&#x2013;5815. doi: 10.1128/JVI.00289-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00289-14</ArticleId><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevots D, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, united states, 1980 through 1991: Implications for estimating the risk of vaccine-associated disease. Archives of Pediatrics &amp; Adolescent Medicine. 1994;148:479&#x2013;485. doi: 10.1001/archpedi.1994.02170050037007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.1994.02170050037007</ArticleId><ArticleId IdType="pubmed">8180638</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CC, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern nigeria. Journal of Virology. 2013;87:4907&#x2013;4922. doi: 10.1128/jvi.02954-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02954-12</ArticleId><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcami A, Ghazal P, Yewdell JW. Viruses in control of the immune system. EMBO Reports. 2002;3:927&#x2013;932. doi: 10.1093/embo-reports/kvf200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/embo-reports/kvf200</ArticleId><ArticleId IdType="pmc">PMC1307615</ArticleId><ArticleId IdType="pubmed">12370204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong, K. C., Devi, S., Cardosa, M. J. &amp; Wong, K. T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol84, 10.1128/JVI.00999-09 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Scientific Reports5, 7878, 10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LC, et al. Enterovirus 71 proteins 2A and 3D antagonize the antiviral activity of gamma interferon via signaling attenuation. Journal of Virology. 2015;89:7028&#x2013;7037. doi: 10.1128/jvi.00205-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00205-15</ArticleId><ArticleId IdType="pmc">PMC4473548</ArticleId><ArticleId IdType="pubmed">25926657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, et al. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. Journal of Virology. 2009;83:6477&#x2013;6483. doi: 10.1128/jvi.00434-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00434-09</ArticleId><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, et al. Type I interferons protect mice against enterovirus 71 infection. Journal of General Virology. 2005;86:3263&#x2013;3269. doi: 10.1099/vir.0.81195-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81195-0</ArticleId><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, et al. A Non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. Journal of Virology. 2012;86:2121&#x2013;2131. doi: 10.1128/jvi.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Partidos CD, Santangelo JD, Osorio JE. Adaptation of enterovirus 71 to adult interferon deficient mice. Plos One. 2013;8:e59501. doi: 10.1371/journal.pone.0059501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059501</ArticleId><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen FH, et al. Enterovirus 71 infection increases expression of interferon-gamma-inducible protein 10 which protects mice by reducing viral burden in multiple tissues. Journal of General Virology. 2013;94:1019&#x2013;1027. doi: 10.1099/vir.0.046383-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.046383-0</ArticleId><ArticleId IdType="pubmed">23288420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, et al. Gamma interferon plays a crucial early antiviral role in protection against west nile virus infection. Journal of Virology. 2006;80:5338&#x2013;5348. doi: 10.1128/JVI.00274-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00274-06</ArticleId><ArticleId IdType="pmc">PMC1472130</ArticleId><ArticleId IdType="pubmed">16699014</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra B, et al. IFN-&#x3b3; Is Required for viral clearance from central nervous system oligodendroglia. The Journal of Immunology. 1999;162:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">9973424</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestwood TR, et al. Gamma interferon (IFN-&#x3b3;) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-&#x3b1;/&#x3b2; receptor-deficient mice. Journal of Virology. 2012;86:12561&#x2013;12570. doi: 10.1128/jvi.06743-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.06743-11</ArticleId><ArticleId IdType="pmc">PMC3497655</ArticleId><ArticleId IdType="pubmed">22973027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei R, et al. A dominant EV71-specific CD4+ T cell epitope is highly conserved among human enteroviruses. Plos One. 2012;7:e51957. doi: 10.1371/journal.pone.0051957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051957</ArticleId><ArticleId IdType="pmc">PMC3522610</ArticleId><ArticleId IdType="pubmed">23251663</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29:6269&#x2013;6275. doi: 10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Brostoff T, et al. MicroRNA reduction of neuronal west nile virus replication attenuates and affords a protective immune response in mice. Vaccine. 2016;34:5366&#x2013;5375. doi: 10.1016/j.vaccine.2016.08.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.063</ArticleId><ArticleId IdType="pmc">PMC5683167</ArticleId><ArticleId IdType="pubmed">27637937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A, et al. Requirement of microRNA-155 for normal immune function. Science. 2007;316:608&#x2013;611. doi: 10.1126/science.1139253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1139253</ArticleId><ArticleId IdType="pmc">PMC2610435</ArticleId><ArticleId IdType="pubmed">17463290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A, et al. Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. The Journal of Neuroscience. 2013;33:5127&#x2013;5137. doi: 10.1523/jneurosci.0600-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0600-12.2013</ArticleId><ArticleId IdType="pmc">PMC6705001</ArticleId><ArticleId IdType="pubmed">23516279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee PTI, Mohamed RAH, Ong SK, Tan KO, Poh CL. Characterization of significant molecular determinants of virulence of Enterovirus 71 sub-genotype B4 in Rhabdomyosarcoma cells. Virus Research. 2017;238:243&#x2013;252. doi: 10.1016/j.virusres.2017.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.07.010</ArticleId><ArticleId IdType="pubmed">28705680</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylander S, Kalies I, Brefeldin A. but not monensin, completely blocks CD69 expression on mouse lymphocytes: Efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. Journal of Immunological Methods. 1999;224:69&#x2013;76. doi: 10.1016/S0022-1759(99)00010-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(99)00010-1</ArticleId><ArticleId IdType="pubmed">10357208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>